Evidence map›Paper›PMID 33626235›Full record

ArticleCancer communications (London, England)2021

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

Jun Ho Yi, Seok Jin Kim, Dok Hyun Yoon, Cheolwon Suh, Myung Hee Chang, Deok Hwan Yang, Jae-Cheol Jo, Shin Young Hyun, Hyeon-Seok Eom, Jeong-Ok Lee and 11 more

Abstract readLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jun Ho YiDivision of Hematology-Oncology, Department of Medicine, Chung-Ang University, Dongjak-gu, Seoul, 06973, Korea.ORCID 0000-0003-1499-7131
Seok Jin KimDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, 06351, Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, 05505, Korea.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, 05505, Korea.
Myung Hee ChangNational Health Insurance Corporation Ilsan Hospital, Ilsandong-gu, Goyang, 10444, Korea.
Deok Hwan YangDepartment of Hemato-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Gwangju, 58128, Korea.
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Dong-gu, Ulsan, 44033, Korea.
Shin Young HyunDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Gangwon-Do, Wonju, 26426, Korea.
Hyeon-Seok EomDepartment of Internal Medicine, National Cancer Center, Goyang-si Gyeonggi-do, Goyang, 10408, Korea.
Jeong-Ok LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Bundang-gu, Seongnam, 13620, Korea.
Ji Hyun KwonDepartment of Internal Medicine, ChungBuk National University Hospital, Chungbuk, Cheongju, 28644, Korea.
Sang Hoon HanDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, 63241, Korea.
Seung-Shin LeeDepartment of Hematology-Oncology, Wonkwang University Hospital, Iksan-daero, Iksan, 54538, Korea.ORCID 0000-0002-8174-6861
Jae-Yong KwakDepartment of Internal Medicine, Jeonbuk National University Medical School, Jeollabuk-do, Jeonju, 54907, Korea.
Se Hyung KimDivision of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University, College of Medicine, Bucheon Hospital, Wonmi-gu, Bucheon, 14584, Korea.
Dae Sik KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Guro-gu, Seoul, 08308, Korea.
Ji Hyun LeeDivision of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Seo-gu, Busan, 49201, Korea.
Sung Yong OhDivision of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Seo-gu, Busan, 49201, Korea.
Hun Mo RyooDepartment of Internal Medicine, Division of Hematology-Oncology, Catholic University of Daegu, Daegu, 42472, Korea.
Hyo Jung KimDivision of Hematology-Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Dongan-gu, Anyang, 14068, Korea.
Won Seog KimDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, 06351, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Mantle-CellAdenineAdultHumansNeoplasm Recurrence, LocalPiperidinesRepublic of KoreaRetrospective StudiesAdenineibrutinibPiperidines

Identifiers

PMID33626235
PMCPMC7968880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.